EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase I)Open Access · CC BY-NC 4.0

Pharmacokinetics, Pharmacodynamics, and Safety of Single‐Dose Luseogliflozin (TS‐071) in Japanese Children and Adolescents With Type 2 Diabetes: A Multicenter, Open‐Label, Parallel‐Group Phase 1 Study

Toru Kikuchi, Hidefumi Nakamura, Hideo Umeuchi, Iwao Kitajima, Tatsuhiko Urakami

Clinical Pharmacology in Drug Development · 2026

DOI: 10.1002/cpdd.70065 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2026. Verfasst von Toru Kikuchi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Saitama Medical University Hospital, Saitama, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Sodium-Glucose Transporter 2 Inhibitors, Sorbitol. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Taisho Pharmaceutical Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to evaluate the pharmacokinetics, pharmacodynamics, and safety of a single dose of luseogliflozin (TS‐071), a sodium–glucose cotransporter 2 (SGLT2) inhibitor, in Japanese children and adolescents with type 2 diabetes, with the goal of informing dose selection for future research. In this multicenter, open‐label, parallel‐group Phase 1 trial, patients aged 9‐17 years received a single oral dose of luseogliflozin at 1.25, 2.5, or 5 mg. Pharmacokinetic and pharmacodynamic parameters were assessed and compared with existing adult data. In total, 19 patients completed the study. The mean age was 14.3 ± 1.9 years, and the mean body weight was 77.28 ± 25.32 kg. Plasma luseogliflozin concentrations increased in a dose‐dependent manner. The maximum plasma concentration and the area under the curve were comparable to those observed in adults. Administration of luseogliflozin at all dose levels resulted in a substantial increase in urinary glucose excretion. No safety concerns emerged from the single‐dose administration. Luseogliflozin demonstrated favorable pharmacokinetic, pharmacodynamic, and safety profiles in pediatric patients, consistent with adult findings. These results support the selection of 2.5‐ and 5‐mg doses for a future Phase 3 pediatric study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Hypoglycemic AgentsSodium-Glucose Transporter 2 InhibitorsSorbitolAdolescentChildFemaleHumansMaleAdministration, OralArea Under CurveBlood GlucoseDose-Response Relationship, DrugGlycated HemoglobinJapan

Stichwörter der Autor:innen

luseogliflozinpediatricpharmacodynamicpharmacokineticstype 2 diabetes

Substanzen

1,5-anhydro-1-(5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl)-1-thioglucitolBlood GlucoseGlycated HemoglobinHypoglycemic AgentsSodium-Glucose Transporter 2 InhibitorsSorbitol

Autor:innen und Institutionen

  • Department of Pediatrics, Saitama Medical University Hospital, Saitama, Japan.
  • Department of Research and Development Supervision, National Center for Child Health and Development, Tokyo, Japan.
  • Development Headquarters, Taisho Pharmaceutical Co. Ltd, Tokyo, Japan.
  • Department of Pediatrics, Nihon University Hospital, Tokyo, Japan.

Förderung

  • Taisho Pharmaceutical Co., Ltd.

Zitieren

APA

Kikuchi, T., Nakamura, H., Umeuchi, H., Kitajima, I., & Urakami, T. (2026). Pharmacokinetics, Pharmacodynamics, and Safety of Single‐Dose Luseogliflozin (TS‐071) in Japanese Children and Adolescents With Type 2 Diabetes: A Multicenter, Open‐Label, Parallel‐Group Phase 1 Study. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.70065

Vancouver

Kikuchi T, Nakamura H, Umeuchi H, Kitajima I, Urakami T. Pharmacokinetics, Pharmacodynamics, and Safety of Single‐Dose Luseogliflozin (TS‐071) in Japanese Children and Adolescents With Type 2 Diabetes: A Multicenter, Open‐Label, Parallel‐Group Phase 1 Study. Clinical Pharmacology in Drug Development. 2026. doi:10.1002/cpdd.70065

BibTeX
@article{Kikuchi2026,
  author = {Kikuchi, Toru and Nakamura, Hidefumi and Umeuchi, Hideo and Kitajima, Iwao and Urakami, Tatsuhiko},
  title = {Pharmacokinetics, Pharmacodynamics, and Safety of Single‐Dose Luseogliflozin (TS‐071) in Japanese Children and Adolescents With Type 2 Diabetes: A Multicenter, Open‐Label, Parallel‐Group Phase 1 Study},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2026},
  doi = {10.1002/cpdd.70065}
}
Kostenlos starten →